This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

The content of this website has been produced in line with the BESPONSA®▼ (inotuzumab ozogamicin) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BESPONSA▼ Prescribing Information for Great Britain click here. BESPONSA▼ Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.

Administration

Administer BESPONSA with precision1

For more information on administration, please consult the BESPONSA Summary of Product Characteristics or download the Pharmacy Guide below

Before administering BESPONSA

UV; ultraviolet

Pre-medication with a corticosteroid, antipyretic, and antihistamine is recommended prior to dosing

  •  For patients with circulating lymphoblasts, cytoreduction with a combination of hydroxyurea, steroids, and/or vincristine to a peripheral blast count ≤ 10,000/mm3 is recommended prior to the first dose

How to administer BESPONSA

  • BESPONSA is diluted to a total nominal volume of 50 mL, and administered at a flow rate of 50 mL/hr at room temperature (68–77 °F [20–25 °C])

During and after administering BESPONSA

Observe patients for ≥ 1 hour post infusion

Patients should be observed during and for at least 1 hour after the end of the infusion for symptoms of infusion-related reactions

Explore more

Fast Facts

Download the Fast Facts PDF document to aid your understanding of BESPONSA. SmPC should be consulted for full guidance

Download here

Pharmacy Guide

Download the guide for Pharmacists for information on dosing, drug interactions, reconstitution, administration, shelf life etc. SmPC should be consulted for full guidance

Download here
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
Reference
  1. BESPONSA Summary of Product Characteristics for Great Britain click here. BESPONSA Summary of Product Characteristics for Northern Ireland click here
PP-INO-GBR-0499. August 2021

Support and resources

Access Support and Resources to read the guidelines or watch videos from leading specialists

Access here

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No